| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2021-09-10 22:45:30 UTC |
|---|
| Update Date | 2022-09-22 17:45:00 UTC |
|---|
| HMDB ID | HMDB0245703 |
|---|
| Secondary Accession Numbers | None |
|---|
| Metabolite Identification |
|---|
| Common Name | 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate |
|---|
| Description | 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate, also known as molsidomin or corvaton, belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively. Based on a literature review a significant number of articles have been published on 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate. This compound has been identified in human blood as reported by (PMID: 31557052 ). 1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
|---|
| Structure | CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1 InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 5-[(Ethoxycarbonyl)amino]-3-(4-morpholinyl)-1,2,3-oxadiazolium inner salt | ChEBI | | CAS 276 | ChEBI | | CAS-276 | ChEBI | | Corraton | ChEBI | | Coruno | ChEBI | | Corvaton | ChEBI | | Covarsal | ChEBI | | MolsiCare | ChEBI | | Molsicor | ChEBI | | Molsidolat | ChEBI | | Molsidomin | ChEBI | | Molsidomina | ChEBI | | Molsidominum | ChEBI | | Morial | ChEBI | | Morsydomine | ChEBI | | Motazomin | ChEBI | | N-(Ethoxycarbonyl)-3-morpholinosydnone imine | ChEBI | | N-Carboxy-3-morpholinosydnone imine ethyl ester | ChEBI | | N-Ethoxycarbonyl-3-morpholinosydnonimine | ChEBI | | SIN-10 | ChEBI | | Sydnopharm | ChEBI | | 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidic acid | Generator | | Molsidain | HMDB | | SIN 10 | HMDB | | Molsidomin stada | HMDB | | Von CT, molsidomin | HMDB | | Molsi 1a pharma | HMDB | | Molsibeta | HMDB | | SIN10 | HMDB | | Molsi-azu | HMDB | | Fali cor | HMDB | | Molsihexal | HMDB | | Molsi azu | HMDB | | Molsidomin ratiopharm | HMDB | | Fali-cor | HMDB | | Korvatone | HMDB | | Molsidomin heumann | HMDB | | Molsidomin-ratiopharm | HMDB | | Molsi puren | HMDB | | Duracoron | HMDB | | MTW-Molsidomin | HMDB | | Heumann, molsidomin | HMDB | | Molsiket | HMDB | | MTW Molsidomin | HMDB | | Molsidomin von CT | HMDB | | Corpea | HMDB | | Molsi-puren | HMDB | | Alpharma brand OF molsidomine | HMDB | | Molsidomine normon brand | HMDB | | Molsidominratiopharm | HMDB | | Stadapharm brand OF molsidomine | HMDB | | CT Arzneimittel brand OF molsidomine | HMDB | | 1a Brand OF molsidomine | HMDB | | Azupharma brand OF molsidomine | HMDB | | Molsidomine ratiopharm brand | HMDB | | Normon brand OF molsidomine | HMDB | | Schwarz brand OF molsidomine | HMDB | | Molsidomine | HMDB | | Molsidomine aventis brand | HMDB | | Molsidomine salutas brand | HMDB | | Molsidomine schwarz brand | HMDB | | Molsidomine CT-arzneimittel brand | HMDB | | Sanol brand OF molsidomine | HMDB | | CT-Arzneimittel brand OF molsidomine | HMDB | | Hexal brand OF molsidomine | HMDB | | Merck dura brand OF molsidomine | HMDB | | Molsidomine heumann brand | HMDB | | Molsidomine stadapharm brand | HMDB | | Salutas brand OF molsidomine | HMDB | | Heumann brand OF molsidomine | HMDB | | Molsidomine betapharm brand | HMDB | | Aventis brand OF molsidomine | HMDB | | Molsidomine azupharma brand | HMDB | | Molsidomine hexal brand | HMDB | | Molsidomine MTW brand | HMDB | | Betapharm brand OF molsidomine | HMDB | | Ratiopharm brand OF molsidomine | HMDB | | MTW Brand OF molsidomine | HMDB | | Molsidomine 1a brand | HMDB | | Molsidomine alpharma brand | HMDB | | Molsidomine sanol brand | HMDB | | Ethyl N-[3-(morpholin-4-yl)-5H-1,2,3λ⁵-oxadiazol-5-ylidene]carbamic acid | HMDB |
|
|---|
| Chemical Formula | C9H14N4O4 |
|---|
| Average Molecular Weight | 242.235 |
|---|
| Monoisotopic Molecular Weight | 242.101504947 |
|---|
| IUPAC Name | 5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3λ⁵-oxadiazol-3-ylium |
|---|
| Traditional Name | 5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3λ⁵-oxadiazol-3-ylium |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCOC(=O)[N-]C1=C[N+](=NO1)N1CCOCC1 |
|---|
| InChI Identifier | InChI=1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3 |
|---|
| InChI Key | XLFWDASMENKTKL-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as morpholines. These are organic compounds containing a morpholine moiety, which consists of a six-member aliphatic saturated ring with the formula C4H9NO, where the oxygen and nitrogen atoms lie at positions 1 and 4, respectively. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Oxazinanes |
|---|
| Sub Class | Morpholines |
|---|
| Direct Parent | Morpholines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Morpholine
- Carbonic acid derivative
- Dialkyl ether
- Ether
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Azacycle
- Oxacycle
- Organooxygen compound
- Organonitrogen compound
- Carbonyl group
- Organic nitrogen compound
- Organic oxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Predicted by Siyang on May 30, 2022 | 10.7876 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 5.71 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1308.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 269.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 119.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 164.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 56.9 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 374.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 535.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 107.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 770.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 308.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1289.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 283.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 286.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 376.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 266.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 112.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate GC-MS (Non-derivatized) - 70eV, Positive | splash10-01dj-7910000000-63f8ea7ee27b88f0912f | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 10V, Positive-QTOF | splash10-0006-6490000000-c5e4bc21cb85b4e60a70 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 20V, Positive-QTOF | splash10-000j-9220000000-abafa3380cf8a5a4d0bd | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 40V, Positive-QTOF | splash10-000l-9400000000-daea7c7e4e6043483506 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 10V, Negative-QTOF | splash10-0006-5290000000-6d4f7dd885c9fb6c59ad | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 20V, Negative-QTOF | splash10-002n-9560000000-93fecea706c4877048ad | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 1-Ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 40V, Negative-QTOF | splash10-052v-9000000000-a53b47a7b42292d341b5 | 2016-08-03 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-10-13 | Wishart Lab | View Spectrum |
|
|---|